WO2002062832A2
(en)
*
|
2001-02-06 |
2002-08-15 |
Merck Patent Gmbh |
Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
|
DE60227367D1
(en)
|
2001-02-06 |
2008-08-14 |
Merck Patent Gmbh |
MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENITY
|
CA2439926A1
(en)
|
2001-03-08 |
2002-09-12 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
|
PL369309A1
(en)
*
|
2001-03-20 |
2005-04-18 |
Merck Patent Gmbh |
Modified insulin with reduced immunogenicity
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
WO2003020761A1
(en)
*
|
2001-09-04 |
2003-03-13 |
Merck Patent Gmbh |
Modified human growth hormone
|
EP1495052B9
(en)
*
|
2002-04-18 |
2009-12-16 |
MERCK PATENT GmbH |
Modified factor viii
|
DE60312330T2
(en)
*
|
2002-06-10 |
2007-11-22 |
Algonomics N.V. |
METHOD FOR PREDICTING THE BINDING SAFFINITY OF MHC PEPTIDE COMPLEXES
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
EP1610825A2
(en)
|
2003-03-31 |
2006-01-04 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
BRPI0416141B8
(en)
|
2003-11-01 |
2021-05-25 |
Biovation Ltd |
modified anti-cd52 antibody, pharmaceutical composition, expression vectors, and method of preparing an immunoglobulin
|
CA2548817A1
(en)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
KR101027427B1
(en)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
Fc VARIANTS WITH INCREASED BINDING TO FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
FI20060200A0
(en)
*
|
2005-04-20 |
2006-02-27 |
Glykos Finland Oy |
Method for analyzing the specificity of sialic acid binding of human influenza virus
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CN101351477B
(en)
|
2005-12-30 |
2011-11-16 |
默克专利有限公司 |
Anti-CD19 antibodies with reduced immunogenicity
|
US20070192033A1
(en)
|
2006-02-16 |
2007-08-16 |
Microsoft Corporation |
Molecular interaction predictors
|
US8396671B2
(en)
|
2006-02-16 |
2013-03-12 |
Microsoft Corporation |
Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
|
US8706421B2
(en)
|
2006-02-16 |
2014-04-22 |
Microsoft Corporation |
Shift-invariant predictions
|
EP2062180A2
(en)
*
|
2006-08-25 |
2009-05-27 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Epitope-protein scaffolds and their use
|
US8121797B2
(en)
|
2007-01-12 |
2012-02-21 |
Microsoft Corporation |
T-cell epitope prediction
|
MX2009013635A
(en)
|
2007-06-25 |
2010-05-19 |
Univ Tulane |
Influenza inhibiting compositions and methods.
|
EP2296688A2
(en)
*
|
2007-10-26 |
2011-03-23 |
Glykos Finland Oy |
Peptide vaccine for influenza virus
|
SI2235059T1
(en)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011119484A1
(en)
*
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
EP2471543A1
(en)
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
GB201109238D0
(en)
|
2011-06-01 |
2011-07-13 |
Antitope Ltd |
Antibodies
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
WO2013096948A1
(en)
|
2011-12-23 |
2013-06-27 |
Lydon Nicholas B |
Immunoglobulins and variants directed against pathogenic microbes
|
EP3539563A1
(en)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Antibody specific for cd22 and methods of use thereof
|
CN104994874B
(en)
|
2012-12-26 |
2017-04-12 |
安科协同公司 |
ANTI- INTEGRIN [beta]1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
|